Relevance section written by JCO Associate Editor Suzanne Lentzsch, MD, PhD. Molecular risk reporting by the International Myeloma Working Group consensus 1 has so far been limited to the high-risk ...

The global molecular cytogenetics market size is calculated at USD 2.78 billion in 2025 and is expected to reach around USD 6 ...

Consistent diagnostic identification of high-risk disease is desirable to address unmet patient need. The aim was to investigate the consistency of association of co-occurrence of high-risk ...

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say researchers from the University of Leeds and The Institute of Cancer Research.

Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America, Inc. (HTA) have revealed the awardees of their OhmX Rapid Application to Market Penetration User Partnership, or OhmX RAMP UP, Grant Program.

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

In this article, we discuss the common reasons for recurrent fetal loss, plus diagnostic procedures to consider in pinpointing the problem, such as cytogenetic studies, blood coagulation protein ...

To Measure is to Predict; Characterization of Response to Therapy in Plasma Cell Disorders ...

Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...

Upper tract urothelial carcinoma (UTUC) is an aggressive disease that is challenging to biopsy and diagnose, frequently yielding nondiagnostic cytology and tissue specimens. Therefore, UTUC is often ...